Rossari Biotech Limited has announced its consolidated financial results for the quarter ended December 31, 2025 (Q3 FY26), reporting continued year-on-year growth despite a softer domestic demand environment. For the quarter ended Q3 FY26, the company reported revenue from operations of ₹581.7 crore, reflecting a 13% year-on-year increase compared to ₹512.7 crore in the corresponding period last year. Operating performance improved during the quarter, with EBITDA rising 6% to ₹68.9 crore from ₹64.8 crore, supported by higher volumes and stable segmental contributions.
EBITDA margin for the quarter stood at 11.8%, compared with 12.6% in Q3 FY25, reflecting the impact of ongoing investments and cost pressures. Despite this moderation in margins, profit after tax increased 3% year-on-year to ₹32.8 crore from ₹31.7 crore. Diluted earnings per share improved to ₹5.9, up from ₹5.7 in the previous year period.
For the nine-month period ended FY26, revenue from operations grew 14% year-on-year to ₹1,711.5 crore, compared with ₹1,500.7 crore in the corresponding period of the previous year. EBITDA for the nine-month period rose 7% to ₹208.7 crore from ₹195.6 crore, reflecting continued scale-up across business segments.
EBITDA margin for the nine-month period stood at 12.2%, compared with 13.0% in 9M FY25. Profit after tax increased marginally to ₹103.2 crore from ₹101.9 crore, while diluted earnings per share rose to ₹18.6 from ₹18.4, indicating steady profitability over the period.
Commenting on the results, Edward Menezes, Promoter and Executive Chairman, and Sunil Chari, Promoter and Managing Director, said the company delivered healthy year-on-year growth during the quarter, supported by balanced contributions across business segments and sustained momentum in international markets.
The Home, Personal Care and Performance Chemicals (HPPC) segment recorded 11% year-on-year growth, reflecting stable demand conditions. Textile Specialty Chemicals (TSC) posted 18% growth, while the Animal Health and Nutrition (AHN) segment grew 39% during the quarter, together supporting overall performance. Export markets continued to contribute positively, driven by efforts to strengthen customer relationships and expand geographic reach.
Profitability during the period was impacted by ongoing investments in capacity expansion, product development and market-entry initiatives. Management noted that these investments are aimed at strengthening long-term competitiveness, with operating leverage, scale benefits and product mix improvement expected to support margins over time.
The company’s phased capacity expansion programme across business verticals remains on track. In addition, the Board has granted in-principle approval for the establishment of greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia. The proposed facilities will be set up through Rossari International Limited Company, a wholly owned subsidiary, subject to regulatory and statutory approvals. The project is expected to enhance supply chain resilience, improve speed-to-market and support long-term international growth, with funding to be evaluated through a mix of equity, debt and internal accruals.
Headquartered in Mumbai, Rossari operates manufacturing facilities at Silvassa and Dahej and serves a wide range of industries including FMCG, home care, industrial cleaning, personal care, textiles, performance chemicals and animal health. The company maintains a strong pan-India distribution network and continues to focus on disciplined execution, customer-driven innovation and sustainable value creation.
